CONgenital CORvitia P

pou

B.J.M. Mulder, AMC Amsterdam E.T. van der Velde, LUMC Leiden J.W.J. Vriend, ICIN C.J.M. Engelfriet-Rijk, ICIN 1. Harms, ICIN H.D.M. Murk Jansen, ICIN L.M. Roffel, ICIN W. Hoekstra, ICIN

Natioa rey and DN k of adults

www.CONCOR.nOt dh ls. a

I

rt

e*H g t S

a

I I n

,1&lllc

-

I

Inclusion results June 30, 2004

B.J.M. Mulder, chairman, ICIN E.T. van der Velde, LUMC Leiden E.C.M. Mariman, AZM Maastricht J.E. Speksnijder, Netherlands Heart Foundation F.J. Meijboom, EMC Rotterdam H.W. Vilegen, LUMC Leiden G. Veen, VUMC Amsterdam P.G. Pieper, AZG Groningen H.W.M. Plokker, UMCU Utrecht A.P.J. van Djk, UMC St. Radboud N!jmegen 0. Danieis, UMCSt Radboud Nijmegen J.L.M. Stappers, AZM Maastricht J.G.P. Tijssen, AMC Amsterdam

*

*

Tetralogy of Fallot Aortic coarctation Aortic valvar stenosis Transposition of great arteries

Pulmonary valvar stenosis * ASD 11 * Marfan syndrome *VSD *

ASD I

p Perimembranous VSD *

jan'02

apr 02

jul'02

oct'02

Jan'03

a03

jul'03

oct'3

feb'04

Jun'04 MO"

*

Subvalvar aortic stenosis Other diagnoses (80 beats/min with or without rate control medication 4. Oral anticoagulation (or aspirin ifno risk factors for thromboembolic complications are present)

Exclusion criteria 1. Paroxysmal AF 2. Known contraindications for either strict or lenient rate control (e.g. previous adverse effects on negative chronotropic drugs) 3. Unstable heart failure defined as NYHA IV heart failure and heart failure necessitating hospital admission